Liabilities / Assets
Score unavailable
Liabilities-to-assets requires both liabilities and assets on the latest valid filing.
EIN 82-3268952 • 501(c)3 • Norco, CA
Profile
Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
Liabilities / Assets
Score unavailable
Liabilities-to-assets requires both liabilities and assets on the latest valid filing.
Liabilities / Revenue
Score unavailable
Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.
Net Margin
6th percentile
Higher net margin than 6% of similar nonprofits.
Top Officer Pay
Score unavailable
No filing with officer rows is available for this organization yet.
Asset Growth
12th percentile
Faster asset growth than 12% of similar nonprofits.
Revenue Growth
12th percentile
Faster revenue growth than 12% of similar nonprofits.
Assets
Down$11,116
Down $41,494 (-79%) from 2020
Liabilities
-
No earlier filing loaded for comparison.
Net Assets
Down$11,116
Down $41,494 (-79%) from 2020
Revenue
Down$21,520
Down $42,428 (-66%) from 2020
Expenses
Up$62,995
Up $35,207 (+127%) from 2020
Net Income
Down-$41,475
Down $77,635 (-215%) from 2020
Most recent year
2021 • Form 990EZDetailed filing. Detailed filing data is available for this year.
Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.
| Description | Grants | Expenses |
|---|---|---|
| WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE. | - | $32,476 |
| OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE. | - | $27,550 |
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| LINDA WHITE | President | PT | $0 | - | - |
| JOSHUA SPIEGEL | Vice Preside | PT | $0 | - | - |
| DAN LANG | Treasurer | PT | $0 | - | - |
| VICKI SUTHERLAND | Secretary | PT | $0 | - | - |
“Expenses advertising 31,465 bank fees 20 merchant fees 561 office expense 1,000 website 392 equipment expense 58 insurance 756 licenses fee 115 professional fees 1,078 total 35,445”
“BOOK/ RETURN DIFF -19”
“Destroy duchennes mission is to complete the cure for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.”
“With the development and rise of gene editing, crispr-cas9, technologies, humanity has a real opportunity to cure virtually all genetic diseases, such as duchenne muscular dystrophy. Gene editing technology has given us the ability to rewrite our dna and correct faulty dna, like mutations that cause diseases. The applications for gene editing to improve the world are nearly endless and we want to be the champion of advancing gene editing to human trials for people with duchenne. It could be said that the current state of gene editing technology, crispr-cas9, is the tool to cure duchenne that needs to be perfected before it can be applied in humans. More scientific studies need to be done to perfect this tool, crispr-cas9, and that is why we so passionately say we need to: complete the cure.”
“Our founder, elijah stacy who is 19 years old, has taken an entire year to write a 100k word autobiography about his life living with duchenne and some of the life lessons he has learned because of it. This book gives an honest and even vulnerable look into what life is really like living with duchenne muscular dystrophy. By properly launching and publicizing the book/elijah's story, we believe we can solve the awareness problem surrounding duchenne muscular dystrophy. We believe this will lead to more drugs being passed by the fda because of a deeper personal understanding of duchenne and we believe it will allow us to raise more funds to accomplish our mission: complete the curetm for duchenne muscular dystrophy by advancing gene-editing and gene therapy technologies, the future of medicine, into human practice.”
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | false |
| IRS990EZ/BooksInCareOfDetail/PersonNm | 0 | SACKETT FINANCIAL GROUP |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 7146719330 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 915 W IMPERIAL HIGHWAY 160 |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | BREA |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | CA |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 92821 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 52610 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt | 0 | 11116 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | false |
| IRS990EZ/ContributionsGiftsGrantsEtcAmt | 0 | 21520 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | false |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | false |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | -41475 |
| IRS990EZ/FiledScheduleAInd | 0 | true |
| IRS990EZ/ForeignFinancialAccountInd | 0 | false |
| IRS990EZ/ForeignOfficeInd | 0 | false |
| IRS990EZ/Form1120PolFiledInd | 0 | false |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 52610 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 11116 |
| IRS990EZ/GrossReceiptsAmt | 0 | 21520 |
| IRS990EZ/InfoInScheduleOPartIIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIInd | 0 | X |
| IRS990EZ/LobbyingActivitiesInd | 0 | false |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | false |
| IRS990EZ/MethodOfAccountingAccrualInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 52610 |
| IRS990EZ/NetAssetsOrFundBalancesEOYAmt | 0 | 11116 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 52610 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 11116 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 30.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 13.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 16.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 20.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | LINDA WHITE |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | JOSHUA SPIEGEL |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | DAN LANG |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | VICKI SUTHERLAND |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | PRESIDENT |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | VICE PRESIDE |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | TREASURER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | SECRETARY |
| IRS990EZ/OperateHospitalInd | 0 | false |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | false |
| IRS990EZ/OrganizationHadUBIInd | 0 | false |
| IRS990EZ/OtherChangesInNetAssetsAmt | 0 | -19 |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 35445 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | false |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | DESTROY DUCHENNES MISSION IS TO COMPLETE THE CURE FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE. |
| IRS990EZ/PrintingPublicationsPostageAmt | 0 | 27550 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 1 | OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 0 | 32476 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 1 | 27550 |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | false |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | false |
| IRS990EZ/SchoolOperatingInd | 0 | false |
| IRS990EZ/SubjectToProxyTaxInd | 0 | false |
| IRS990EZ/TanningServicesProvidedInd | 0 | false |
| IRS990EZ/TotalExpensesAmt | 0 | 62995 |
| IRS990EZ/TotalProgramServiceExpensesAmt | 0 | 60026 |
| IRS990EZ/TotalRevenueAmt | 0 | 21520 |
| IRS990EZ/TransactionWithControlEntInd | 0 | false |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | false |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990EZ/WebsiteAddressTxt | 0 | WWW.DESTROYDUCHENNE.ORG |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt | 0 | 21520 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt | 0 | 63948 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt | 0 | 85468 |
| IRS990ScheduleA/PublicOrganization170Ind | 0 | X |
| IRS990ScheduleA/PublicSupportCY170Pct | 0 | 1.00000 |
| IRS990ScheduleA/PublicSupportPY170Pct | 0 | 1.00000 |
| IRS990ScheduleA/PublicSupportTotal170Amt | 0 | 85468 |
| IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind | 0 | X |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt | 0 | 21520 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt | 0 | 63948 |
| IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt | 0 | 85468 |
| IRS990ScheduleA/TotalSupportAmt | 0 | 85468 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | EXPENSES ADVERTISING 31,465 BANK FEES 20 MERCHANT FEES 561 OFFICE EXPENSE 1,000 WEBSITE 392 EQUIPMENT EXPENSE 58 INSURANCE 756 LICENSES FEE 115 PROFESSIONAL FEES 1,078 TOTAL 35,445 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | BOOK/ RETURN DIFF -19 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | DESTROY DUCHENNES MISSION IS TO COMPLETE THE CURE FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | WITH THE DEVELOPMENT AND RISE OF GENE EDITING, CRISPR-CAS9, TECHNOLOGIES, HUMANITY HAS A REAL OPPORTUNITY TO CURE VIRTUALLY ALL GENETIC DISEASES, SUCH AS DUCHENNE MUSCULAR DYSTROPHY. GENE EDITING TECHNOLOGY HAS GIVEN US THE ABILITY TO REWRITE OUR DNA AND CORRECT FAULTY DNA, LIKE MUTATIONS THAT CAUSE DISEASES. THE APPLICATIONS FOR GENE EDITING TO IMPROVE THE WORLD ARE NEARLY ENDLESS AND WE WANT TO BE THE CHAMPION OF ADVANCING GENE EDITING TO HUMAN TRIALS FOR PEOPLE WITH DUCHENNE. IT COULD BE SAID THAT THE CURRENT STATE OF GENE EDITING TECHNOLOGY, CRISPR-CAS9, IS THE TOOL TO CURE DUCHENNE THAT NEEDS TO BE PERFECTED BEFORE IT CAN BE APPLIED IN HUMANS. MORE SCIENTIFIC STUDIES NEED TO BE DONE TO PERFECT THIS TOOL, CRISPR-CAS9, AND THAT IS WHY WE SO PASSIONATELY SAY WE NEED TO: COMPLETE THE CURE. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 4 | OUR FOUNDER, ELIJAH STACY WHO IS 19 YEARS OLD, HAS TAKEN AN ENTIRE YEAR TO WRITE A 100K WORD AUTOBIOGRAPHY ABOUT HIS LIFE LIVING WITH DUCHENNE AND SOME OF THE LIFE LESSONS HE HAS LEARNED BECAUSE OF IT. THIS BOOK GIVES AN HONEST AND EVEN VULNERABLE LOOK INTO WHAT LIFE IS REALLY LIKE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY. BY PROPERLY LAUNCHING AND PUBLICIZING THE BOOK/ELIJAH'S STORY, WE BELIEVE WE CAN SOLVE THE AWARENESS PROBLEM SURROUNDING DUCHENNE MUSCULAR DYSTROPHY. WE BELIEVE THIS WILL LEAD TO MORE DRUGS BEING PASSED BY THE FDA BECAUSE OF A DEEPER PERSONAL UNDERSTANDING OF DUCHENNE AND WE BELIEVE IT WILL ALLOW US TO RAISE MORE FUNDS TO ACCOMPLISH OUR MISSION: COMPLETE THE CURETM FOR DUCHENNE MUSCULAR DYSTROPHY BY ADVANCING GENE-EDITING AND GENE THERAPY TECHNOLOGIES, THE FUTURE OF MEDICINE, INTO HUMAN PRACTICE. |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | FORM 990-EZ, PART I, LINE 16 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | FORM 990-EZ, PART I, LINE 20 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | FORM 990-EZ, PART III |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | FORM 990-EZ, PART III, LINE 28 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 4 | FORM 990-EZ, PART III, LINE 29 |
| ReturnHeader/BuildTS | 0 | 2022-09-23 18:48:47Z |
| ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd | 0 | true |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | DAN LANG |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | TREASURER |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 9514448147 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2022-03-04 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | DESTROY DUCHENNE |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | DEST |
| ReturnHeader/Filer/EIN | 0 | 823268952 |
| ReturnHeader/Filer/PhoneNum | 0 | 9514448147 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 3182 VANDERMOLEN DR |
| ReturnHeader/Filer/USAddress/CityNm | 0 | NORCO |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | CA |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 92860 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmEIN | 0 | 330946321 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt | 0 | SACKETT FINANCIAL GROUP |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt | 0 | 915 W IMPERIAL HWY STE 160 |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm | 0 | BREA |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd | 0 | CA |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd | 0 | 92821 |
| ReturnHeader/PreparerPersonGrp/PhoneNum | 0 | 7146719330 |
| ReturnHeader/PreparerPersonGrp/PreparationDt | 0 | 2022-03-04 |
| ReturnHeader/PreparerPersonGrp/PreparerPersonNm | 0 | BRAID DEWEESE CPA |
| ReturnHeader/ReturnTs | 0 | 2022-03-10T18:13:19-06:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm | 0 | DAN |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm | 0 | LANG |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2021-01-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2021-12-31 |
| ReturnHeader/TaxYr | 0 | 2021 |
No mirrored PDF or thumbnail assets are attached yet.